William Blair analyst Ryan Daniels has maintained their bullish stance on PHR stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ryan Daniels has given his Buy rating due to a combination of factors that highlight Phreesia’s strong financial performance and positive outlook. The company reported impressive first-quarter results for fiscal 2026, surpassing market expectations in both revenue and adjusted EBITDA. This strong performance was supported by a 15% year-over-year increase in revenue, reaching $115.9 million, and an adjusted EBITDA of $20.8 million, which significantly exceeded the consensus estimate of $16.7 million.
Additionally, Phreesia demonstrated robust operational metrics, with an increase in average health services clients by 9% and a rise in total revenue per client. Management’s decision to modestly raise the adjusted EBITDA outlook while maintaining revenue guidance further underscores confidence in the company’s growth trajectory. The solid start to the fiscal year and the strategic positioning of Phreesia as a core player in the healthcare IT sector reinforce the Buy rating.
Based on the recent corporate insider activity of 163 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHR in relation to earlier this year.